Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Emerging Vector-Borne Diseases in North America.

Created on 21 Nov 2026

Authors

David Shahbodaghi, Nicholas Rathjen

Published in

American family physician. Volume 114. Issue 5. Pages 513-518.

Abstract

Vector-borne diseases are a significant and growing public health concern. They account for approximately 20% of infectious diseases globally and cause more than 700,000 deaths each year. These diseases are caused by viral, bacterial, or parasitic pathogens most commonly transmitted through the bites of infected mosquitoes and ticks. In the United States, emerging viral infections include West Nile, dengue, chikungunya, and Zika; emerging bacterial infections include human monocytic ehrlichiosis, human granulocytic anaplasmosis, and Rocky Mountain spotted fever. Bacterial infections often require early recognition and prompt treatment with doxycycline. Increasing incidence of vector-borne diseases is closely linked with environmental changes, climate shifts, urbanization, and increased interaction with vector habitats. Preventive strategies include minimizing skin exposure with appropriate clothing, using insecticide-treated bed nets, and applying insect repellents containing 20% to 30% N, N-diethyl-m-toluamide (DEET) or 20% picaridin. Applying permethrin to clothing provides additional protection. Because many vectors are active during the day-particularly Aedes mosquitoes and most ticks-protective measures should extend beyond nighttime exposure.

PMID:
43062870
Bibliographic data and abstract were imported from PubMed on 21 Nov 2026.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 8
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement